SEARCH

SEARCH BY CITATION

References

  • 1
    Owen RG, Treon SP, Al-Katib A, et al. Clinicopathological definition of Waldenström's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenström's Macroglobulinemia. Semin Oncol 2003;30:11015.
  • 2
    Berger F, Isaacson PG, Piris MA, et al. Lymphoplasmacytic lymphoma/Waldenström macroglobulinemia. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, eds. Pathology and genetics of tumours of haematopoietic and lymphoid tissues. Lyon, France: IARC Press, 2001. 1324.
  • 3
    Dimopoulos MA, Kyle RA, Anagnostopoulos A, et al. Diagnosis and management of Waldenstrom's macroglobulinemia. J Clin Oncol 2005;23:156477.
  • 4
    Swerdlow SH, Berger F, Pileri SA, et al. Lymphoplasmacytic lymphoma. In: Swerdlow SH, Campo, E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman W, eds. WHO classification of tumours of haematopoietic and lymphoid tissues, 4th edn. Lyon, France: IARC Press, 2008. 1945.
  • 5
    Anderson KC, Alsina M, Bensinger W, et al. Waldenström's macroglobulinemia/lymphoplasmacytic lymphoma, version 2.2013. J Natl Compr Canc Netw 2012;10:12119.
  • 6
    Percy C, Van Holten V, Muir C. International classification of diseases for oncology (ICD-O), 2nd edn. Geneva, Switzerland: World Health Organization, 1990.
  • 7
    Fritz A, Percy C, Jack A, et al., eds. International classification of diseases for oncology, 3rd edn. Geneva, Switzerland: World Health Organization, 2000.
  • 8
    Morton LM, Wang SS, Devesa SS, et al. Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 2006;107:26576.
  • 9
    Phekoo KJ, Jack RH, Davies E, et al. The incidence and survival of Waldenström's Macroglobulinaemia in South East England. Leuk Res 2008;32:559.
  • 10
    Treon SP, Hunter ZR, Aggarwal A, et al. Characterization of familial Waldenstrom's macroglobulinemia. Ann Oncol 2006;17:48894.
  • 11
    Royer RH, Koshiol J, Giambarresi TR, et al. Differential characteristics of Waldenstrom macroglobulinemia according to patterns of familial aggregation. Blood 2010;15:446471.
  • 12
    Kristinsson SY, Björkholm M, Goldin LR, et al. Risk of lymphoproliferative disorders among first-degree relatives of lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia patients: a population-based study in Sweden. Blood 2008;112:30526.
  • 13
    Kristinsson SY, Koshiol J, Björkholm M, et al. Immune-related and inflammatory conditions and risk of lymphoplasmacytic lymphoma or Waldenstrom macroglobulinemia. J Natl Cancer Inst 2010;102:55767.
  • 14
    Morton LM, Turner JJ, Cerhan JR, et al. Proposed classification of lymphoid neoplasms for epidemiologic research from the Pathology Working Group of the International Lymphoma Epidemiology Consortium (InterLymph). Blood 2007;110:695708.
  • 15
    Carreon JD, Morton LM, Devesa SS, et al. Incidence of lymphoid neoplasms by subtype among six Asian ethnic groups in the United States, 1996–2004. Cancer Causes Control 2008;19:117181.
  • 16
    Parkin DM, Whelan SL, Ferlay J, et al. Cancer incidence in five continents, Vols. I–VIII. Lyon, France: IARC Press, 2005.
  • 17
    The Research Group for Population-based Cancer Registration in Japan. Cancer incidence and incidence rates in Japan in 1988: estimates based on data from ten population-based cancer registries. Jpn J Clin Oncol 1994;24:299304.
  • 18
    Marugame T, Kamo K, Katanoda K, et al. Cancer incidence and incidence rates in Japan in 2000: estimates based on data from 11 Population-based cancer registries. Jpn J Clin Oncol 2006;36:66875.
  • 19
    Sobue T. Current activities and future directions of the cancer registration system in Japan. Int J Clin Oncol 2008;13:97101.
  • 20
    The method for national estimates of cancer incidence based on population-based cancer registry, the Center for Cancer Control and Information Services, National Cancer Center, Japan. Available at: http://ganjoho.jp/professional/statistics/statistics_02.html. [Japanese] Accessed on March 19, 2013.
  • 21
    Taiwan Cancer Registry. Available at: http://tcr.cph.ntu.edu.tw/main.php?Page=N1. Accessed on March 19, 2013.
  • 22
    Chiang CJ, Chen YC, Chen CJ, et al. Cancer trends in Taiwan. Jpn J Clin Oncol 2010;40:897904.
  • 23
    Turner JJ, Morton LM, Linet MS, et al. InterLymph hierarchical classification of lymphoid neoplasms for epidemiologic research based on the WHO classification (2008): update and future directions. Blood 2010;116:e908.
  • 24
    Wang H, Chen Y, Li F, et al. Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer 2012;118:3793800.
  • 25
    Ahmad OB, Boschi-Pinto C, Lopez AD, et al. Age standardization of rates: new WHO standard. GPE Discussion paper series No.31. Geneva: World Health Organization, 2000.
  • 26
    Klein RJ, Schoenborn CA. Age adjustment using the 2000 projected US population. Healthy People 2000 Stat Notes 2001;20:19.
  • 27
    Joinpoint Regression Program, Version 3.3.1, April 2008. Statistical Research and Applications Branch, National Cancer Institute.
  • 28
    Groves FD, Travis LB, Devesa SS, et al. Waldenström's macroglobulinemia: incidence patterns in the United States, 1988–1994. Cancer 1998;82:107881.
  • 29
    Waxman AJ, Mink PJ, Devesa SS, et al. Racial disparities in incidence and outcome in multiple myeloma: a population-based study. Blood 2010;116:55016.
  • 30
    Cohen HJ, Crawford J, Rao MK, et al. Racial differences in the prevalence of monoclonal gammopathy in a community-based sample of the elderly. Am J Med 1998;104:43944.
  • 31
    Landgren O, Weiss BM. Patterns of monoclonal gammopathy of undetermined significance and multiple myeloma in various ethnic/racial groups: support for genetic factors in pathogenesis. Leukemia 2009;23:16917.
  • 32
    Iwanaga M, Tagawa M, Tsukasaki K, et al. Prevalence of monoclonal gammopathy of undetermined significance: study of 52,802 persons in Nagasaki City, Japan. Mayo Clin Proc 2007;82:14749.
  • 33
    Aoki R, Karube K, Sugita Y, et al. Distribution of malignant lymphoma in Japan: analysis of 2260 cases, 2001–2006. Pathol Int 2008;58:17482.
  • 34
    Kyle RA, Therneau TM, Rajkumar SV, et al. Prevalence of monoclonal gammopathy of undetermined significance. N Engl J Med 2006;354:13629.
  • 35
    Lee LN, Jan IS, Tien HF, et al. Laboratory and clinical characterization of monoclonal gammopathy in Taiwanese. J Formos Med Assoc 2002;101:917.
  • 36
    Kyle RA, Therneau TM, Rajkumar SV, et al. Long-term follow-up of IgM monoclonal gammopathy of undetermined significance. Blood 2003;102:375964.
  • 37
    Kristinsson SY, Goldin LR, Björkholm M, et al. Genetic and immune-related factors in the pathogenesis of lymphoproliferative and plasma cell malignancies. Haematologica 2009;94:15819.
  • 38
    Han X, Kilfoy B, Zheng T, et al. Lymphoma survival patterns by WHO subtype in the United States, 1973–2003. Cancer Causes Control 2008;19:84158.
  • 39
    The population aged 65 years old and over. Statistics Bureau and the Director-General for Policy Planning of Japan. Available at: http://www.stat.go.jp/data/topics/topi181.htm. [Japanese]. Accessed on March 19, 2013.
  • 40
    Department of Statistics, Ministry of Interior, Taiwan. Available at: http://www.moi.gov.tw/stat/life.aspx. [Chinese] Accessed on March 19, 2013.